NCT06615284View on ClinicalTrials.gov

A Study of Atorvo+™ in Healthy Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

May 14, 2025

Study Completion Date

July 1, 2025

Conditions
Coronary Heart DiseaseDyslipidemias
Interventions
DRUG

Atorvo+™ (Arm1)

Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).

DRUG

Atorvo+™ +CBD (Arm 2)

Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).

DRUG

Atorvo+™ +CBD (Arm 3)

Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).

Trial Locations (1)

Unknown

RECRUITING

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Indication Bioscience LLC

INDUSTRY

NCT06615284 - A Study of Atorvo+™ in Healthy Adult Participants | Biotech Hunter | Biotech Hunter